-
Product Insights
Peripheral Neuropathy (Sensory Neuropathy) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Neuropathy (Sensory Neuropathy) - Drugs In Development, 2023’, provides an overview of the Peripheral Neuropathy (Sensory Neuropathy) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Neuropathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuropathy - Drugs In Development, 2023’, provides an overview of the Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tremelimumab in Endometrial Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tremelimumab in Endometrial Cancer Drug Details: Tremelimumab (Imjudo) is a human monoclonal monospecific antibody against...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SBT-101 in Adrenomyeloneuropathy (AMN)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SBT-101 in Adrenomyeloneuropathy (AMN) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SBT-101 in Adrenomyeloneuropathy (AMN) Drug Details: SBT-101 is under development for the...
-
Company Profile
Syncona Ltd – Company Profile
Syncona Ltd (Syncona) is a closed-ended investment company. Its services include founding, building, and funding companies. The company makes investments in life sciences companies including gene therapy, cell therapy, biologics, and small molecule fields. Syncona’s portfolio companies include Freeline Therapeutics, SwanBio Therapeutics, Neogene Therapeutics, Autolus, Quell Therapeutics, Anveon, Achilles Therapeutics, Clade Therapeutics, Purespring Therapeutics, OMass Therapeutics, and Resolution Therapeutics. The company also provides Syncona Platform which helps to transform scientific research into companies. It serves healthcare, biotechnology, pharmaceutical, life sciences,...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SBT-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SBT-101 Drug Details SBT-101 is under development for the treatment of adrenomyeloneuropathy (AMN). It...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SBT-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SBT-101 Drug Details SBT-101 is under development for the treatment of triple-negative breast cancer,...